Page last updated: 2024-10-24

busulfan and Epithelial Neoplasms

busulfan has been researched along with Epithelial Neoplasms in 1 studies

Research Excerpts

ExcerptRelevanceReference
"However, most women (75%) with advanced epithelial ovarian cancer (EOC) will relapse following surgery and chemotherapy."2.53Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer. ( Lane, G; Montes, A; Seshadri, S; Wuntakal, R, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wuntakal, R1
Seshadri, S1
Montes, A1
Lane, G1

Reviews

1 review available for busulfan and Epithelial Neoplasms

ArticleYear
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
    The Cochrane database of systematic reviews, 2016, Jun-29, Issue:6

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Busulfan; Carcinoma, Ovar

2016